NCT04093323 2026-02-25
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Roswell Park Cancer Institute
Phase 2 Terminated
Clinical Trials
7 trialsNCT01100528 2019-02-26
Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00613509 2016-04-14
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Sanofi
Phase 2 Terminated
NCT00026143 2013-06-05
Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00963664 2009-09-09
Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma
NeoPlas Innovation
Phase 2 Withdrawn
NCT00911443 2009-07-09
Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma
sigma-tau i.f.r. S.p.A.
Phase 2 Completed
NCT00308607 2009-04-03
Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma
University of Turku
Phase 2 Completed